Amneal Expects Host Of New Launches To Drive Firm To Success
US Firm Is One Of Few Generics Players Growing In Difficult Market
Executive Summary
Despite a couple of setbacks during Q2, Amneal has sustained continual growth across its business, particularly in the injectables space.
You may also be interested in...
Who’s Hired? Stada Appoints New UK Head
Summer’s end brings notable leadership reshuffles across four continents and five companies. Stada has appointed its head of mid-sized European markets as its UK lead while Gustavo Pesquin joins Amneal from Sanofi.
Multiple Vasostrict ANDAs Rival Eagle In Competitive Market
Amphastar, Amneal and Aurobindo are among ANDA sponsors confirming USFDA approval for generic versions of Endo’s Vasostrict (vasopressin) 20 units/ml single-dose vial – as first mover Eagle Pharmaceuticals remains locked in patent-litigation proceedings with the originator.
Amneal Spreads Bets On Generics Amid Focus On High-Barrier Opportunities
Amneal highlighted the benefits of a broad spread of generics and an increased shift towards complex products with high barriers to entry, as it reported generics sales growth in Q1 despite a tough operating environment for US generics.